Dendritic cell vaccine to prevent COVID-19

Phase 1

• Conditions: COVID-19 (SARS-CoV-2 infection) vaccine; Infections and Infestations; COVID-19 (SARS-CoV-2 infection)

• Registration Number: ISRCTN14037053
• Lead Sponsor: Ministry of Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-31
• Last Update Posted: 11 January 2021
• Study Completion: 2022-01-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

1. 18 years or older
2. In relatively good health with adequate physical and mental function
3. Increased risk for medical complications associated with COVID-19 infection or increased risk for exposure to SARS-CoV-2

Exclusion Criteria

1. Active COVID-19 infection by PCR testing
2. Pre-existing IgG or IgM SARS-CoV-2 antibodies
3. Pregnant, Known hypersensitivity to GM-CSF
4. Known active immune deficiency disease or active HIV
5. HBV, HCV, On active treatment with corticosteroids or other immunosuppressive agent
6. Participated in previous COVID-19 vaccine study

Study & Design

• Study Type: Interventional
• Study Design: Not specified